Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib vs teriflunomide in relapsing multiple sclerosis with open-label remibrutinib extension
jRCT2071220034Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: Annualized relapse rate (ARR) of confirmed relapses (core part). Started Feb 2023; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2071220034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220034.